BERKELEY, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it will host a conference call on the web to share additional initial clinical data from its ANTLER Phase 1 clinical trial of CB-010 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (r/r-B-NHL) on Friday, June 10, 2022 at 8:00 a.m. ET. The discussion will include longer duration data on the six patients treated at dose level 1 based on a new data deadline.
Webcast presenters will include:
- Rachel Haurwitz, Ph.D., President and CEO, Caribou
- Syed Rizvi, MD, Chief Medical Officer, Caribou
- Steven Kanner, Ph.D., Scientific Director, Caribou
- Loretta J. Nastoupil, MD, new drug development section chief; Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center
- James H. Essell, MD, OHC hematologist, medical oncologist, blood and bone marrow transplant specialist, and chairman, Cell Therapy, US Oncology Network
The live webcast and conference call at 8:00 a.m. ET, along with a presentation, will be available under Events in the Investors section of the company’s website. To join the conference call, dial 1-844-862-9351 (domestic) or 1-929-517-0932 (international) and reference conference ID #4657536. The archived audio webcast will be available on Caribou’s website after the call and will be available for 30 days.
Details of the poster presentation at EHA are as follows:
Title: First-in-human trial of CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with PD-1 knockout, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma ( ANTLER study)
Presenter: Loretta J. Nastoupil, MD
Date and time: Friday, June 10, 2022, 4:30 p.m. – 5:45 p.m. CEST (10:30 a.m. – 11:45 a.m. ET)
Session title: Gene therapy, cell immunotherapy and vaccination – Clinic
Location: Messe Wien Exhibition & Congress Center, Vienna, Austria
Presentations and posters will be available to EHA registered attendees for on-demand viewing on the EHA website on June 10, 2022 at 9:00 a.m. CEST (3:00 a.m. ET). Caribou expects to issue a press release on the data at 9:00 a.m. CEST (3:00 a.m. ET) on Friday, June 10, 2022. The poster will be available on the Presentations page of the Investors section of Caribou’s website.
CB-010 is the lead product candidate of Caribou’s CAR-T allogeneic cell therapy platform and is being evaluated in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL ) in the ongoing ANTLER Phase 1 trial. CB-010 is an allogeneic anti-CD19 CAR-T cell therapy designed using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to insert a CD19-specific CAR into the TRAC gene and knock out PD-1 to stimulate persistence of antitumor activity. CB-010 is the first in-clinic allogeneic CAR-T cell therapy with a PD-1 knockout. Additional information about the ANTLER trial is available at https://clinicaltrials.gov using the identifier NCT04637763.
About Caribou’s New Next Generation CRISPR Platform
CRISPR genome editing uses easy-to-design, modular biological tools to make changes to DNA in living cells. There are two basic components of CRISPR class 2 systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific double-strand break, leading to a change in the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which can lead to adverse effects on cell function and phenotype. In response to this challenge, Caribou has developed hybrid CRISPR RNA-DNA guides (chRDNA; pronounced “chardonnays”) that direct much more precise genome editing compared to all-RNA guides. Caribou deploys the power of its Cas12a chRDNA technology to perform high-efficiency multiple modifications, including multiplex gene insertions, to develop CRISPR-modified therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies specifically designed for enhanced persistence. Caribou is advancing a pipeline of ready-to-use CAR-T and CAR-NK cell therapies for the treatment of patients with hematological malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements relating to Caribou’s strategy, plans and objectives, as well as expectations regarding its clinical and preclinical development. programs, including its expectations regarding the timing of the release of initial and additional patient data from its ANTLER Phase 1 clinical trial for CB-010. Management believes that these forward-looking statements are reasonable as made. However, these forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from future results expressed or implied by the forward-looking statements. Risks and uncertainties include, but are not limited to, risks inherent in the development of cell therapy products; uncertainties relating to the initiation, cost, timing, progress and results of Caribou’s current and future research and development programs, preclinical studies and clinical trials; and the risk that data from initial or interim clinical trials may ultimately not be predictive of the safety and efficacy of Caribou’s product candidates or that clinical results may differ as more patient data becomes available; as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and filings later. In light of the material uncertainties in these forward-looking statements, you should not rely on the forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to publicly update forward-looking statements for any reason.